| Name | Title | Contact Details |
|---|
At OPTIMUM, an architecture, furniture, and technology (A/F/T) products collective, were not defined by size or the number of product lines but by our unique design-thinking approach. We believe in solving workplace challenges by optimizing the integration of architecture, furniture, and technology to create seamless experiences for those who design, plan, deliver, and occupy spaces. What sets us apart is our focus on offering aesthetically appealing, high-performance products that balance design and cost-efficiency, along with our partnerships with flexible manufacturers who can customize solutions to meet specific needs. Success isnt about individual pieces; its about the synergy that happens when people, elements, and solutions come together, resulting in outcomes far greater than the sum of their parts. This philosophy drives everything we do at OPTIMUM as we enhance the environments where we live, work, learn, and heal.
For 27 years and counting, SLAM has been the most authentic brand in basketball storytelling. What started as a magazine in 1994 has now grown into a global lifestyle brand and multimedia property with 20-plus social channels, a burgeoning merchandise division and multiple franchise events annually. With over 16 million engaged followers across the globe, SLAM and its channels reach fans of the NBA, WNBA, college and high school, and the worlds of fashion, sneakers, gaming and more in a unique and trusted voice. The cover of SLAM remains the Holy Grail for basketball players; if you want to play in the NBA or WNBA, you want to be on the cover of SLAM.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.